11 / 21
Page 74
allied
academies
Journal of Neurology and Neurorehabilitation Research | Volume 3
November 26-27, 2018 | Dubai, UAE
Spine and Spine Disorders
Addiction Research and Therapy
3rd International Conference on
International Conference on
Joint Event
&
Introducing precision addiction management of Reward Deficiency Syndrome, the construct that
underpins all addictive behaviors
Kenneth Blum
University of Florida, USA
W
orldwide, daily there are several millions of people
increasingly unable to combat their frustrating and
even fatal romance with getting high; for some ‘high’ may
be just experiencing “normal” feelings of well-being. The
National Institutes on Alcohol Abuse and Alcoholism and on
Drug Abuse (among others) conduct and fund outstanding
research using Sophisticated Neuroimaging and Molecular
Genetic Applied Technology to improve understanding of the
intricate functions of brain reward circuitry and resting sate
functional connectivity, that is purportedly playing a key role in
the addiction symptomatology. There is controversy as to the
ultimate definition of addiction involving ASAM, ISAM, on one
hand and other psychological and World Health Organizations
on the other hand. From a Neuroscience perspective, while it
is widely accepted that dopamine is a major neurotransmitter
implicated in behavioral and chemical addictions, there remains
controversy about how to modulate dopamine clinically in
order to treat and prevent various types of addictive disorders.
While for themost partMedication Assisted Treatments (MATS)
promote dopamine blockade or unintentional dopamine
down–regulation in the long term, adherence and relapse
prevention has been poor. This is especially true even for even
for Buprenorphine–naloxone combinations. It appears, though,
that a prudent approachmay be a biphasic short-termblockade
followed by long-term dopaminergic upregulation, with the
goal of enhancing the functional connectivity within the brains
rewardcircuitry, possibly targeting therewarddeficiencyandthe
stress-like anti- reward symptomatology arising in the context
of addiction. Such phenotypes can be characterized using the
Genetic Addiction Risk Score (GARS)™ Dopamine homeostasis
may thus be achieved via customization of neuronutrient
supplementation (Putative pro-dopamine regulation) based on
the GARS test result developed by our group, dubbed “Precision
Addiction Management” (PAM)™ along with a behavioral
intervention.
e:
drd2gene@gmail.com